Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984805 | 0.90 | PTGS2 (0.41) | PTGS1PTGS2ALOX5GABBR2GABBR1 | |
| SCHEMBL5984432 | 0.79 | PTGS1 (0.34) | PTGS1PTGS2ALOX5GABBR2GABBR1 | |
| SCHEMBL5984285 | 0.72 | FFAR1 (0.40) | GABBR2GABBR1ALDH1A1TSHRHPGD | |
| SCHEMBL85764 | 0.70 | GABBR2 (0.66) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL1668238 | 0.69 | GABBR2 (0.42) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL8534660 | 0.69 | GABBR2 (0.46) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL11864278 | 0.69 | GABBR2 (0.50) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 | |
| Water SCHEMBL1502206 | 0.69 | GABBR2 (0.63) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31385524 | 0.69 | GABBR2 (0.63) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 | |
| Water SCHEMBL1502204 | 0.69 | GABBR2 (0.63) | PTGS1PTGS2GABBR2GABBR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-6835754-B2 | Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example | RENOVIS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6730700-B2 | 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6342523-B1 | DRUGS AND ANTIINFLAMMATORY AGENTS | CENTAUR PHARMACEUTICALS, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1135367-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Centaur Pharmaceuticals, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032567-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | PTGS1 95/4885PTGS2 217/4885ALOX5 400/4885 |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | PTGS1 13/4885PTGS2 86/4885ALOX5 106/4885 |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | PTGS1 16/4885PTGS2 109/4885ALOX5 106/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | PTGS1 77/4885PTGS2 198/4885ALOX5 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.